BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Zanubrutinib: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: BeOne Medicines, Genfleet Therapeutics (Shanghai) Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-31 est. | P3 | BeOne Medicines ONC | NCT04170283 A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutini | B-cell Malignancies | active not recruiting | 955 |
| 2026-12-31 est. | P1/P2 | Genfleet Therapeutics (Shanghai) Inc. | NCT06375733 A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | Large B-cell Lymphoma | recruiting | 51 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | BeOne Medicines ONC | NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | active not recruiting | 94 |
| 2026-09-22 | P2 | BeOne Medicines ONC | NCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglo | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobuli | active not recruiting | 114 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.